Smart jab can shrink head and neck cancer tumours within six weeks, trial finds

Recent trial results reveal that a new triple-action therapy drug, amivantamab, can significantly shrink head and neck cancer tumors within just six weeks. This is particularly important as head and neck cancer is the sixth most common cancer globally, and current treatment options can be limited for recurrent or metastatic cases. The encouraging findings from this trial could pave the way for more effective treatment strategies, offering hope to patients facing this challenging diagnosis.